Belharra Therapeutics
Yvonne Schmidt is an accomplished medicinal chemist with extensive experience in pharmaceutical research and development. Currently, Yvonne serves as the Director of Medicinal Chemistry at Belharra Therapeutics since January 2022, following a role as Principal Scientist at Inception Therapeutics. Previously, at Vertex Pharmaceuticals, Yvonne excelled as Research Scientist II, leading projects in chemistry automation and sodium channel programs while managing collaborations with contract research organizations. Earlier roles include a postdoctoral position at UC Irvine and contributions as a scientific coworker at Albert-Ludwigs-Universität Freiburg. Yvonne holds a Dr. rer. nat. in Organic Chemistry and a Diplom in Chemistry from the University of Freiburg.
This person is not in any offices
Belharra Therapeutics
Belharra Therapeutics is a privately held drug discovery company that is disrupting the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform. Belharra scientists can identify small molecule drug candidates for any binding site, on any protein, in any conformational state, and in any cell type using its chemoproteomicsplatform. Belharra is based in the San Francisco Bay Area, with its primary lab and offices in San Diego.